Research record
BRAF + MEK inhibitor combinations
BRAF/MEK combinations are mutation-specific targeted therapies. They are relevant when the melanoma has a qualifying BRAF V600 mutation, not simply because melanoma is aggressive.
What this is
BRAF/MEK combinations are mutation-specific targeted therapies. They are relevant when the melanoma has a qualifying BRAF V600 mutation, not simply because melanoma is aggressive.
Why it may come up
- adjuvant
- cannot be removed by surgery
- has spread
- BRAF V600 confirmed
What not to assume
- Do not apply BRAF/MEK logic to NRAS melanoma.
- Confirm variant and country label.
At a glance
BRAF + MEK inhibitor combinations
- Type
- Targeted therapy
- Mutation result
- BRAF V600E, BRAF V600K
- Where
- US, Global
- Evidence status
- Approved in listed place
- Last checked
- 2026-05-20
What we know
- FDA pages support encorafenib/binimetinib in cannot be removed by surgery or has spread BRAF V600E/V600K melanoma.
- FDA pages support dabrafenib/trametinib in adjuvant BRAF V600E/V600K melanoma with lymph-node involvement after complete resection.
What is unclear
- Do not apply BRAF/MEK logic to NRAS melanoma.
- Confirm variant and country label.
Questions to ask
- Which BRAF variant is documented?
- Is this adjuvant, has spread, or trial-framed use?
- If immunotherapy is also an option, how is sequencing being discussed?
Timeline
- approval2018: BRAF/MEK approval context
Source-backed BRAF V600 melanoma targeted therapy context.